The company hopes to commercialize the assay, and is pursuing a larger validation study, but may face competitors who have also staked claims for this indication.
The assay is designed to quantitate HBV DNA in serum or plasma to assist in the treatment of chronic HBV-infected patients receiving antiviral therapy.
Qiagen's partnership and merger agreement with NeuMoDx may help it compete with high-volume molecular testing vendors such as Abbott, Hologic, and Roche.
Researchers integrated results from a pathogen-host association study with available clinical data to find variants influencing both infection responses and other disease risks.
The new assay simultaneously detects four viral targets in donated blood plasma in a single sample and can add value to the biologics development space.
Independent research teams identified and sequenced hepatitis B strains going back thousands of years from samples in Europe, uncovering now-extinct lineages.
Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.
